tafasitamab

Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Endpoints
Mon, 03/2/20 - 09:37 am
MorphoSys
Gilead Sciences
Novartis
CAR-T
tafasitamab
DLBCL
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Mon, 01/13/20 - 11:51 pm
Incyte
MorphoSys
lymphoma
tafasitamab
Morphosys to take on CAR-Ts in NHL with promising antibody
Pharmaforum
Mon, 05/20/19 - 11:02 pm
MorphoSys
Celgene
Revlimid
non-Hodgkin lymphoma
clinical trials
tafasitamab
Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead
Endpoints
Fri, 05/17/19 - 01:03 pm
CAR-T
MorphoSys
Novartis
Gilead Sciences
tafasitamab
DLBCL